Skip to main content
SpringerLink
Log in

Folate, antifolates, and folate analogs in Pediatric Oncology

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Farber S, Diamond LK, Mercer RD, Sylvester RF Jr, Wolff JA: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). New England Journal of Medicine 238:787–793, 1948.

    Google Scholar 

  2. Franklin AL, Belt M, Stokstad ELR, Jukes TH: Biological studies with 4-amino-10-methylpteroyl-glutamic acid. Journal of Biological Chemistry 177:621–629, 1949.

    Google Scholar 

  3. Goldin A, Venditti JM, Humphreys SR, Mantel N: A quantitative comparison of the antileukemic effectiveness of two folic acid antagonists in mice. Journal of the National Cancer Institute 15:1657–1664, 1955.

    Google Scholar 

  4. Chu E, Takimota CH: Antimetabolites. In De Vita VT, Hellman S, Rosenburg SA (eds) Cancer: Principles & Practice of Oncology, 4th Ed, pp 358–374. Philadelphia, Lippincott, 1993.

    Google Scholar 

  5. Matherly LH, Barlowe CK, Goldman ID: Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells. Cancer Research 46:588–593, 1986.

    Google Scholar 

  6. Fabre I, Fabre G, Goldman ID: Polyglutamylation, an important element in methorexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cell in vitro. Cancer Research 44:3190–3195, 1984.

    Google Scholar 

  7. Allegra CJ, Fine RL, Drake JC, et al.: The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells: evidence for direct inhibition of purine synthesis. Journal of Biological Chemistry 261:6478–6486, 1986.

    Google Scholar 

  8. Allegra CJ, Hoang K, Yeh GC, et al.: Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cancer cells as a principal mode of metabolic inhibition by methotrexate. Journal of Biological Chemistry 262:13520–13526, 1987.

    Google Scholar 

  9. Takimoto CH, Allegra CJ: New antifolates in clinical development. Oncology 9:649–659, 1995.

    Google Scholar 

  10. Chu E, Takimoto CH, Voeller D, Grem JL, Allegra CJ: Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro. Biochemistry 32:4756–4760, 1993.

    Google Scholar 

  11. Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 266:1821–1828, 1994.

    Google Scholar 

  12. Slansky JE, Li Y, Kaelin WG, Farnham PJ: A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Molecular and Cellular Biology 13(3):1610–1618, 1993.

    Google Scholar 

  13. Sholar PW, Baram J, Seither R, et al.: Inhibition of folate-dependent enzymes by 7-OH-methotrexate. Biochemical Pharmacology 37:3531–3534, 1988.

    Google Scholar 

  14. Zoubek A, Zaunschirm HA, Lion T, et al.: Successful carboxypeptidase G2 rescue in delayed MTX-elimination due to renal failure. Pediatric Hematology and Oncology 12:471–477, 1995.

    Google Scholar 

  15. Adamson PC, Balis FM, McCully CL, Godwin KS, Poplack DG: Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. Journal of Clinical Oncology 10(8):1359–1364, 1992.

    Google Scholar 

  16. Hum M, Kamen BA: Annotation to Successful carboxypeptidase G2 rescue in delayed MTX-elimination due to renal failure. Pediatric Hematology and Oncology 12(6):521–524, 1995.

    Google Scholar 

  17. Grant SC, Kris MG, Young CW, Sirotnak FM: Edatrexate, an antifolate with antitumor activity: a review. Cancer Investigation 11:36–45, 1993.

    Google Scholar 

  18. Sirotnak FM, Schmid FA, Samuels LL, et al.: 10-Ethyl-10-deaza-aminopterin: Structural design and biochemical, pharmacologic and antitumor properties. NCI Monograph 5:127–131, 1987.

    Google Scholar 

  19. Sirotnak FM, Donsbach RC: Comparative studies on the transport of aminopterin, methorexate, and methasquin by the L1210 leukemia cell. Cancer Research 32:2120–2126, 1972.

    Google Scholar 

  20. Sirotnak FM, De Graw JI, Moccio DM, Samuels LL, Goutas LJ: New folate analogs of the 10-deaza-aminopterin series: Basis for structure design and biochemical and pharmacologic properties. Cancer Chemotherapy and Pharmacology 12:18–25, 1984.

    Google Scholar 

  21. Rumberger BG, Barrueco JR, Sirotnak FM: Differing specificities for 4-aminofolate analogues of folylpolyglutamyl synthetase from tumors and proliferative intestinal epithelium of the mouse with significance for selective antitumor action. Cancer Research 50:4639–4643, 1990.

    Google Scholar 

  22. Schmidt FA, Sirotnak FM, Otter GM, De Graw JI: Combination chemotherapy with a new folate analog. Activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models. Cancer Chemotherapy Reports 71:727–732, 1987.

    Google Scholar 

  23. Kris MG, Kinahan JJ, Gralla RJ, et al.: Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. Cancer Research 48:5573–5579, 1988.

    Google Scholar 

  24. Sirotnak FM, Donsbach RC: A basis for the difference in toxicity of methotrexate, aminopterin and methasquin in mice. Biochemical Pharmacology 24:156–158, 1975.

    Google Scholar 

  25. Philips FS, Sirotnak FM, Sodergren JE, Hutchinson DJ: Uptake of methotrexate, aminopterin and methasquin and inhibition of dihydrofolate reductase and of DNA synthesis in mouse small intestine. Cancer Research 33:153–158, 1973.

    Google Scholar 

  26. Tan C, Meyers P, Steinherz P, et al.: Phase I clinical and pharmacologic study of 10-ethyl-10-deaza-aminopterin (10-EDAM) in children with advanced cancer. Proceedings of the American Association for Cancer Research 29:230, 1988 (abstract).

    Google Scholar 

  27. Garrow TA, Shane B: Purification and general properties of human folylpolyglutamate synthetase. In Chemistry and Biology of Pteridines and Folates, JE Ayling et al. (eds.), Plenum Press, New York, 1993.

    Google Scholar 

  28. Whitehead VM, Rosenblatt DS, Vuchich MJ, Shuster JJ, White A, Beaulieu D: Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: A pilot prognostic factor analysis. Blood 76(10):44–49, 1990.

    Google Scholar 

  29. Whitehead VM, Vuchich MJ, Lauer SJ, Mahoney D, Carroll AJ, Shuster JJ, Esseltine DW, Payment C, Look AT, Akabutu J, Bowen T, Taylor LD, Camitta B, Pullen DJ: Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (> 50 chromosomes) B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Blood 80(5):1316–1323, 1992.

    Google Scholar 

  30. Fulton B, Wagstaff AJ, McTavish D: Trimetrexate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocysitis carinii pneumonia. Drugs 49(4):563–576, 1995.

    Google Scholar 

  31. Kamen BA, Eibl B, Cashmore A, Bertino J: Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]-quinazoline), a nonclassical antifolate, in methotrexate-resistant leukemia cells in vitro, Biochemical Pharmacology 33:1697–1699, 1984.

    Google Scholar 

  32. Rodenhuis S, McGuire JJ, Ramaswamy N, Bertino JR: Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. Cancer Research 46:6513–6419, 1986.

    Google Scholar 

  33. Li W-W, Lin JT, Tong WT, Trippett TM, Brennan MF, et al. Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Research 52:1434–1438, 1992.

    Google Scholar 

  34. Pappo AS, Vats T, Williams TE, Bernstein M, Kamen BA: Phase I trial of trimetrexate in pediactric solid tumors: A Pediatric Oncology Group Study. Medical and Pediatric Oncology 21:280–282, 1993.

    Google Scholar 

  35. Pappo AS, Dubowy R, Ravindranath Y, Alvarado C, Rao S, Whitehead VM, Vega R, Kamen BA, Vietti T: Phase II trial of trimetrexate in the treatment of recurrent childhood acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Journal of the National Cancer Institute 82:1641–1642, 1990.

    Google Scholar 

  36. Balis FM, Patel R, Luks E, Doherty KM, Holcenberg JS, Poplack DG: Pediatric phase I trial and pharmacokinetic study of trimetrexate. Cancer Research 47:4973–4976, 1992.

    Google Scholar 

  37. Fleming GF, Schilsky RL: Antifolates: The next generation. Seminars in Oncology 19(6):707–719, 1992.

    Google Scholar 

  38. Jackman AL, Taylor GA, Gibson W, et al.: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Research 51:5579–5586, 1991.

    Google Scholar 

  39. Jackman AL, Gibson W, Stephens TC, et al.: Biochemical mechanisms involved in the activity of the folatebased thymidylate synthase inhibitor, ICI D1694, Annals of Oncology 3:92, 1992 (abstract) (suppl 1).

    Google Scholar 

  40. Erlichman C: Novel chemotherapeutic agents in clinical development. Current Opinions in Oncology 3:1037–1042, 1991.

    Google Scholar 

  41. Stephens TC, Valcaccia BE, Sheader ML, Hughes LR, Jackman A: The thymidylate synthase (TS) inhibitor ICI D1694 is superior to CB3717, 5fluorouracil (5-FU) and methotrexate (MTX) against a panel of human tumour xenografts. Proceedings of the American Association for Cancer Research 32:328, 1991.

    Google Scholar 

  42. Clarke SJ, Ward J, de Boer M, et al.: Phase I study of the new thymidylate synthase inhibitor Tomudex (ZD1694). Annals of Oncology 5:240, 1994.

    Google Scholar 

  43. Sorenson JM, Jordan E, Grem JL, et al.: Phase I trial of ZD1694 (Tomudex), a direct inhibitor of thymidylate synthase. Annals of Oncology 5:241, 1994.

    Google Scholar 

  44. Beardsley GP, Moroson BA, Taylor EC, et al.: A new folate antimetabolite, 5,10-dideaza-aminopterin and 5,6,7,8-tetrahydrofolate, is a potent inhibitor of de novo purine synthesis. Journal of Biological Chemistry 264:328–333, 1989.

    Google Scholar 

  45. Baldwin SW, Tse A, Gossett LS, et al.: Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase. Biochemistry 30:1997–2006, 1991.

    Google Scholar 

  46. Pizzorno G, Sololoski JA, Cashmore AR, et al.: Intracellular metabolism of 5,10-dideaza-tetrahydrofolic acid in human leukemia cell lines. Molecular Pharmacology 39:85–98, 1991.

    Google Scholar 

  47. Grindey GB, Alati T, Shih C: Reversal of the toxicity but not the antitumor activity of lometrexol by folic acid. Proceedings of the American Association for Cancer Research 32:324, 1991 (abstract).

    Google Scholar 

  48. Li W-W, Bertino JR: Inability of leucovorin to rescue a naturally methotrexate-resistant human soft tissue sarcoma cell line from trimetrexate cytotoxicity. Cancer Research 52:6866–6870, 1992.

    Google Scholar 

  49. Matherly, LH, Taub JW, Ravindranath Y, Proefke SA, Wong SC, Gimotty P, Buck S, Wright JE, Rosowsky A: Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 85(2):500–509, 1995.

    Google Scholar 

  50. Fry DW, Besserer JA: Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired infux as a mechanism of resistance to lipophilic antifolates. Cancer Research 48:9686–9691, 1998.

    Google Scholar 

  51. Lacerda JF, Göker E, Kheradpour A, Dennig D, Elisseyeff Y, Jagiello C, O'Reilly RJ, Bertino JR: Selective treatment of SCID mice bearing methotrexatetransport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection. Blood 85(10):2675–2679, 1995.

    Google Scholar 

  52. Trippelt T, Schlemmer, S, Elisseyeff Y, Göker E, Wachter M, Steinherz, P, Tan C, Berman E, Wright JE, Rosowsky A, Schweitzer B, Bertino JR: Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood 80(5):1158–1162, 1992.

    Google Scholar 

  53. Smith A, Hum M, Winick NJ, Kamen BA: A case for the use of aminopterin in treatment of patients with leukemia based on metabolic studies of blast in vitro. Clinical Cancer Research 2(1):69–73, 1996.

    Google Scholar 

  54. Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. Journal of Clinical Investigation 92:2675–2682, 1993.

    Google Scholar 

  55. Kamen BA: Folic acid antagonists. In: Metabolism and Action of Anti-Cancer Drugs, Powis G and Prough RA (eds), pp 141–155. New York, Taylor and Francis, 1987.

    Google Scholar 

  56. Jacobsen KA, Trivedi BK, Churchill PC, Williams M: Novel therapeutics acting via purine receptors. Biochemical Pharmacology 41:1399–1410, 1991.

    Google Scholar 

  57. Rall TW: Drugs used in the treatment of asthma. In Gilman AG, Rall TW, Nies A, Taylor P (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. New York: Pergamon Press, 1990, 618–637.

    Google Scholar 

  58. Bernini JC, Fort DW, Griener JC, Kane BJ, Chappell WB, Kamen BA: Aminophylline for methotrexate-induced neurotoxicity. The Lancet 345:544–547, 1995.

    Google Scholar 

  59. Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K: Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis and Rheumatism 32(9):1065–1073, 1989.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of Texas Southwestern Medical School, 75235, Dallas, TX, USA

    Martina C. Hum & Barton A. Kamen

Authors
  1. Martina C. Hum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barton A. Kamen
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Address for offprints: UT Southwestern Medical School, Pediatric Hematology/Oncology, 5323 Harry Hines Blvd., Dallas TX 75235-9063, USA

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hum, M.C., Kamen, B.A. Folate, antifolates, and folate analogs in Pediatric Oncology. Invest New Drugs 14, 101–111 (1996). https://doi.org/10.1007/BF00173686

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00173686

Key words

Search

Navigation